ETEX Corporation Announces FDA Clearance and Launch of Carrigen(R) Porous Bone Substitute Material  
3/9/2010 11:47:33 AM

CAMBRIDGE, Mass., March 9 /PRNewswire/ --ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGenĀ® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.